Negative effects of tumor cell nitric oxide on anti-glioblastoma photodynamic therapy

Abstract

Glioblastomas are highly aggressive brain tumors that can persist after exposure to conventional chemotherapy or radiotherapy. Nitric oxide (NO) produced by inducible NO synthase (iNOS/NOS2) in these tumors is known to foster malignant cell proliferation, migration, and invasion as well as resistance to chemo- and radiotherapy. Minimally invasive photodynamic therapy (PDT) sensitized by 5-aminolevulinic acid (ALA)-induced protoporphyrin IX (PpIX) is a highly effective anti-glioblastoma modality, but it is also subject to NO-mediated resistance. Studies by the authors have revealed that glioblastoma U87 and U251 cells use endogenous iNOS/NO to not only resist photokilling after an ALA/light challenge, but also to promote proliferation and migration/invasion of surviving cells. Stress-upregulated iNOS/NO was found to play a major role in these negative responses to PDT-like treatment. Our studies have revealed a tight network of upstream signaling events leading to iNOS induction in photostressed cells and transition to a more aggressive phenotype. These events include activation or upregulation of pro-survival/pro-expansion effector proteins such as NF-κB, phosphoinositide-3-kinase (PI3K), protein kinase-B (Akt), p300, Survivin, and Brd4. In addition to this upstream signaling and its regulation, pharmacologic approaches for directly suppressing iNOS at its activity vs. transcriptional level are discussed. One highly effective agent in the latter category is bromodomain and extra-terminal (BET) inhibitor, JQ1, which was found to minimize iNOS upregulation in photostressed U87 cells. By acting similarly at the clinical level, a BET inhibitor such as JQ1 should markedly improve the efficacy of anti-glioblastoma PDT.

Keywords

Glioblastoma / photodynamic therapy / nitric oxide / inducible NO synthase

References

[1] Louis DN,Wiestler OD.The 2007 WHO classification of tumours of the central nervous system..Neuropathol2007;114:97-109 PMCID:PMC1929165

[2] Behin A,Carpentier AF.Primary brain tumours in adults..The Lancet2003;361:323-31

[3] Wen PY.Malignant gliomas in adults..New Engl J Med2008;359:492-507

[4] Stewart DJ,Eapen L.Cisplatin and radiation in the treatment of tumors of the central nervous system: pharmacological considerations and results of early studies..Int. J Radiat Oncol Biol Phys1994;28:531-42

[5] Yang LJ,Lin ZX.Temozolomide and radiotherapy for newly diagnosed glioblastoma multiforme: a systematic review..Cancer Investig2014;32:31-6

[6] Miranda A,Sousa J,Vitorino C.Breaching barriers in glioblastoma. Part 1: molecular pathways and novel treatment approaches..Int J Pharm2017;531:372-88

[7] Bouzinab K,Zhang J.In serach of effective therapies to overcome resistance to temozolomide in brain tumors..Cancer Drug Resist2019;2:1018-31

[8] Quirk BJ,Donlon S.Photodynamic therapy (PDT) for brain tumors: where do we stand?.Photodiagn Photodyn Ther2015;12:530-44

[9] Bechet D,Guillemin F.Photodynamic therapy of malignant brain tumours: a complementary approach to conventional therapies..Cancer Treat Rev2014;40:229-41

[10] Cramer SW.Photodynamic therapy for the treatment of glioblastoma..Front Surg2020;6:81 PMCID:PMC6985206

[11] Casas A,Ortel B.Tumor cell lines resistant to ALA-mediated photodynamic therapy and possible tools to target surviving cells..Int J Oncol2006;29:397-405

[12] Casas A,Hasan T.Mechanisms of resistance to photodynamic therapy..Curr Med Chem2011;18:2486-515 PMCID:PMC3780570

[13] Girotti AW.Upregulation of nitric oxide in tumor cells as a negative adaptation to photodynamic therapy..Lasers in Surg Med2018;50:590-8

[14] Fahey JM.Nitric oxide antagonism to anti-glioblastoma photodynamic therapy: mitigation by inhibitors of nitric oxide generation..Cancers2019;11:231 PMCID:PMC6406633

[15] Thomas DD,Kantrow SP.The biological lifetime of nitric oxide: implications for the perivascular dynamics of NO and O2..Proc Natl Acad Sci U S A2001;98:355-60 PMCID:PMC14594

[16] Gantner BN,Bonini MG.Nitric oxide in cellular adaptation and disease..Redox Biol2020;34:101550 PMCID:PMC7235643

[17] Knowles RG.Nitric oxide synthases in mammals..Biochem J1994;298:249-58 PMCID:PMC1137932

[18] Alderton WK,Knowles RG.Nitric oxide synthases: structure, function and inhibition..Biochem J2001;357:593-615 PMCID:PMC1221991

[19] Lechner M,Rieder J.Inducible nitric oxide synthase (iNOS) in tumor biology: two sides of the same coin..Sem Cancer biol2005;5:277-89

[20] Vannini F,Nath N.The dual role of iNOS in cancer..Redox Biol2015;6:334-3 PMCID:PMC4565017

[21] Kamm A,Kuban-Jankowska A.Nitric oxide and its derivatives in the cancer battlefield..Nitric Oxide2019;93:102-14

[22] Thomas DD,Isenberg JS.The chemical biology of nitric oxide: implications in cellular signaling..Free Radic Biol Med2008;45:18-31 PMCID:PMC2572721

[23] Heinrich TA,Miranda KM,Wink DA.Biological nitric oxide signaling: chemistry and terminology..Br J Pharmacol2013;169:1417-29 PMCID:PMC3724101

[24] Jahani-Asi A.iNOS: a potential therapeutic target for malignant glioma..Curr Mol Med2013;13:1241-9 PMCID:PMC4266467

[25] Tran AN,Walker K.NOS expression and NO function in glioma and implications for patient therapies..Antiox Redox Signal2017;26:986-99 PMCID:PMC5467121

[26] Foster HW,Stamler JS.Protein S-nitrosylation in health and disease: a current perspective..Trends Mol Med2009;15:391-404 PMCID:PMC3106339

[27] Thomas DD.S-nitrosation: current concepts and new developments..Antiox Redox Signal2012;17:924-36 PMCID:PMC3411337

[28] Hogg N.The chemical biology of S-nitrosothiols..Antiox Redox Signal2012;17:969-80 PMCID:PMC3411335

[29] Fionda C,Santoni A.Immunoregulatory and effector activities of nitric oxide and reactive nitrogen species in cancer..Curr Med Chem2016;23:2618-36

[30] Turchi JJ.Nitric oxide and cisplatin resistance: NO easy answers..Proc Natl Acad Aci USA2006;103:4337-8 PMCID:PMC1450170

[31] Eyler CE,Yan K.Glioma stem cell proliferation and tumor growth are promoted by nitric oxide synthase-2..Cell2011;146:53-66 PMCID:PMC3144745

[32] Dougherty TJ,Henderson BW.Photodynamic therapy..J Natl Cancer Inst1998;90:889-905 PMCID:PMC4592754

[33] Agostinis P,Cengel KA.Photodynamic therapy of cancer: an update..CA Cancer j Clin2011;61:250-81 PMCID:PMC3209659

[34] dos Santos AG,Ferreira L,Labriola L.Photodynamic therapy in cancer treatment..J. Cancer Metastasis Treat2019;5:25

[35] Whelan HT.High-grade glioma/glioblastoma multiforme: is there a role for photodynamic therapy?.J Natl Compr Canc Netw.2012;1:S31-34

[36] Akimoto J.Photodynamic Therapy for Malignant Brain Tumors..Neurol Med Chir (Tokyo)2016;56:151-7 PMCID:PMC4831940

[37] Siddik ZH.Cisplatin: mode of cytotoxic action and molecular basis of resistance..Oncogene2003;22:7265-79

[38] Falk-Mahapatra R.Photodynamic therapy and immunity: an update..Photochem Photobiol2020;96:550-9 PMCID:PMC7293553

[39] Kennedy JC.Endogenous protoporphyrin IX, a clinically useful photosensitizer for photodynamic therapy..J. Photochem. Photobiol B1992;14:275-92

[40] Peng Q,Moan J,Nesland JM.5-Aminolevulinic acid-based photodynamic therapy: principles and experimental research..Photochem. Photobiol1997;65:235-51

[41] Mahmoudi K,Bouras A.5-aminolevulinic acid photodynamic therapy for the treatment of high-grade gliomas..J. Neuro-Oncol2019;141:595-607 PMCID:PMC6538286

[42] Stummer W,Novotny A.In vitro and in vivo porphyrin accumulation in C6 glioma cells after exposure to 5-aminolevulinic acid..J Photochem Photobiol B1998;45:160-9

[43] Colditz MJ,Jeffree RL.Aminolevulinic acid (ALA)-protoporphyrin IX fluorescence guided tumour resection. Part 2: theoretical, biochemical and practical aspects..J Clin Neurosci2012;19:1611-6

[44] Yang X,Kraus D.Aminolevulinic acid-based tumor detection and therapy: molecular mechanisms and strategies for enhancement..Int J Mol Sci2015;16:25856-80 PMCID:PMC4632830

[45] Henderson BW,Vaughan LA.Potentiation of photodynamic therapy antitumor activity in mice by nitric oxide synthase inhibitors is fluence rate-dependent Photochem..Photobiol1999;70:64-71

[46] Korbelik M,Shibuya H.Nitric oxide production by tumor tissue: impact on the response to photodynamic therapy..Br. J Cancer2000;82:1835-43 PMCID:PMC2363231

[47] Reeves KL,Brown NJ.The role of nitric oxide in the treatment of tumors with aminolaevulinic acid-induced photodynamic therapy..J. Photochem Photobiol B: Biology2010;101:224-32

[48] Rapozzi V,Bonavida B.Dual roles of nitric oxide in the regulation of tumor cell response and resistance to photodynamic therapy..Redox Biol2015;6:311-7 PMCID:PMC4556768

[49] Casas A,Fukuda H.Photodynamic therapy of activated and resting lymphocytes and its antioxidant adaptive response..Lasers Med Sci2002;17:42-50

[50] Palasuberniam P,Kraus D,Myers KA.ABCG2 transporter inhibitor restores the sensitivity to triple negative breast cancer cells to aminolevulinic acid-mediated photodynamic therapy..Sci Rep2015;5:13298 PMCID:PMC4539603

[51] Bhowmick R.Signaling events in apoptotic photokilling of 5-aminolevulinic acid-treated tumor cells: inhibitory effects of nitric oxide..Free Radic Biol Med2009;47:731-40 PMCID:PMC2761093

[52] Bhowmick R.Cytoprotective induction of nitric oxide synthase in a cellular model of 5-aminolevulinic-based photodynamic therapy..Free Radic Biol Med2010;48:1296-301 PMCID:PMC2856718

[53] Bhowmick R.Rapid upregulation of cytoprotective nitric oxide in breast tumor cels subjected to a photodynamic therapy-like oxidative challenge..Photochem Photobiol2011;87:378-86 PMCID:PMC3048913

[54] Bhowmick R.Pro-survival and pro-growth effects of stress-induced nitric oxide in a prostate cancer photodynamic therapy model..Cancer Lett2014;343:115-22 PMCID:PMC3874260

[55] Fahey JM.Accelerated migration and invasion of prostate cancer cells after a photodynamic therapy-like challenge: role of nitric oxide..Nitric Oxide2015;49:47-55 PMCID:PMC4545398

[56] Fahey JM,Korytowski W,Girotti AW.Antagonistic effects of endogenous nitric oxide in a glioblastoma photodynamic therapy model..Photochem Photobiol2016;92:842-53 PMCID:PMC5161550

[57] Lancaster JR.The use of diaminofluorescein for nitric oxide detection; conceptual and methodological distinction between NO and nitrosation..Free Radic Biol Med2010;49:1145

[58] Fahey JM.Nitric oxide-mediated resistance to photodynamic therapy in a human breast tumor xenograft model: improved outcome with NOS2 inhibitors..Nitric Oxide2017;62:52-61 PMCID:PMC5215003

[59] Fahey JM,Girotti AW.Upstream signaling events leading to elevated production of pro-survival nitric oxide in photodynamically-challenged glioblastoma cells..Free Radic Biol Med2019;137:37-45 PMCID:PMC6526063

[60] Stamenkovic I.Matrix metalloproteinases in tumor invasion and metastasis..Cenin Cancer Biol2000;10:415-33

[61] Korbelik M.Role of cell stress signaling networks in cancer cell death and antitumor immune response following proteotoxic injury inflicted by photodynamic therapy..Lasers Surg Med2018;50:491-8

[62] Huang B,Zhow MM,Chen LF.Brd4 coactivates transcriptional activation of NF-κB via specific binding of acetylated RelA..Mol Cell Biol2009;29:1375-87 PMCID:PMC2643823

[63] Fahey JM,Smith BC.Nitric oxide antagonism to glioblastoma photodynamic therapy and mitigation thereof by BET bromodomain inhibitor JQ1..J Biol Chem2018;293:5345-59 PMCID:PMC5892570

[64] Shikima N,La Thangue NB.The p300/CBP family: integrating signals with transcription factors and chromatin..Trends Cell Biol1997;7:230-6

[65] Goodman RH.CBP/p300 in cell growth, transformation, and development..Genes Dev2000;14:1553-77

[66] Zin ZH.The roles of SIRT1 in cancer..Genes Cancer2013;4:97-104 PMCID:PMC3764469

[67] Vivanco I.The phosphatidylinositol 3-kinase/Akt pathway in human cancer..Nat Rev Canc2002;2:489-501

[68] Niziolek M,Girotti AW.Chain-breaking antioxidant and cytoprotective action of nitric oxide on photodynamically stressed tumor cells..Photochem Photobiol2003;78:262-70

[69] Zareba M,Korytowski W.Merocyanine 540-sensitized photokilling of leukemia cells: role of post-irradiation chain peroxidation of plasma membrane lipids as revealed by nitric oxide protection..Biochim Biophys Acta2005;1722:51-9

[70] Rubbo H,Trujillo M.Nitric oxide regulation of superoxide and peroxynitrite-dependent lipid peroxidation..J Biol Chem1994;269:26066-75

[71] Korbelik M,Sluiter W.PDT-induced nitrosative stress. SPIE International Symposium on Biomedical Optics,2002;

[72] Park HS,Kim MS,Choi EJ.Nitric oxide negatively regulates c-Jun N-terminal kinase/stress-activated protein by means of S-nitrosylation..Proc Natl Acad Sci USA2000;97:14382-7 PMCID:PMC18927

[73] Li CQ.Nitric oxide as a modulator of apoptosis..Cancer let2005;226:1-15

[74] Azad N,Tantishaiyakul V,Leonard SS.S-nitrosylation of Bcl-2 inhibits its ubiquitin-proteasomal degradation a novel antiapoptotic mechanism that suppresses apoptosis..J BIOL CHEM2006;281:34124-34

[75] Guan WP,Chen XJ,Yan JQ.Nitrosylation of mitogen activated protein kinase phosphatase-1 suppresses radiation-induced apoptosis..Cancer Lett2012;314:137-46

[76] Stomberski CT,Stamler JS.Protein S-nitrosylation: determinants of specificity and enzymatic regulation of S-nitrosothiol-based signaling..Antiox Redox Signal2017;10:1331-51 PMCID:PMC6391618

[77] Matsumoto H,Hatashita M.Induction of radioresistance by a nitric oxide-mediated bystander effect..Radiat Res2001;155:387-96

[78] Yakovlev VA.Role of nitric oxide in the radiation-induced bystander effect..Redox Biol2015;6:396-400 PMCID:PMC4572387

[79] Bazak J,Wawak K,Girotti AW.Enhanced aggressiveness of bystander cells in an anti-tumor photodynamic therapy model: role of nitric oxide produced by targeted cells..Free Radic Biol Med2017;102:111-21

[80] Bazak J,Girotti AW.Bystander effects of nitric oxide in cellular models of anti-tumor photodynamic therapy..Cancers (Basel)2019;11:1674 PMCID:PMC6895962

[81] Hansel TT,Donnelly LE.A selective inhibitor of inducible nitric oxide synthase inhibits exhaled breath nitric oxide in healthy volunteers and asthmatics..FASEB J2003;17:1298-317

[82] Singh D,Knowles RG.Selective inducible initric oxide synthase inhibition has no effect on allergen challenge in asthma..Am J Respir Crit Care Med2007;176:988-93

[83] Shu S.BET bromodomain proteins as cancer therapeutic targets..Cold Spring Harb Symp Quant Biol2016;81:123-9

[84] Filippakopoulos P,Picaud S.Selective inhibition of BET bromodomains..Nature2010;468:1067-173 PMCID:PMC3010259

[85] Filippakopoulos P.Targeting bromodomains: epigenetic readers of lysine acetylation..Nat Rev Drug Discov2014;13:337-56

[86] Lam FC,Wyckoff J.Enhanced efficacy of combined temozolomide and bromodomain inhibitor therapy for gliomas using targeted nanoparticles..Nat Commun2018;9:1991 PMCID:PMC5959860